218 related articles for article (PubMed ID: 32563213)
1. Regorafenib in patients with advanced Child-Pugh B hepatocellular carcinoma: A multicentre retrospective study.
Kim HD; Bang Y; Lee MA; Kim JW; Kim JH; Chon HJ; Kang B; Kang MJ; Kim I; Cheon J; Hwang JE; Kang JH; Byeon S; Hong JY; Ryoo BY; Lim HY; Yoo C
Liver Int; 2020 Oct; 40(10):2544-2552. PubMed ID: 32563213
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic effects of regorafenib after sorafenib monotherapy with advanced hepatocellular carcinoma including Child-Pugh classification B: A retrospective observational study.
Komiyama S; Numata K; Ogushi K; Moriya S; Fukuda H; Chuma M; Maeda S
Medicine (Baltimore); 2020 Jul; 99(29):e21191. PubMed ID: 32702881
[TBL] [Abstract][Full Text] [Related]
3. Real-world systemic sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Korea.
Lee MJ; Chang SW; Kim JH; Lee YS; Cho SB; Seo YS; Yim HJ; Hwang SY; Lee HW; Chang Y; Jang JY
Invest New Drugs; 2021 Feb; 39(1):260-268. PubMed ID: 32749658
[TBL] [Abstract][Full Text] [Related]
4. Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma.
Kelley RK; Mollon P; Blanc JF; Daniele B; Yau T; Cheng AL; Valcheva V; Marteau F; Guerra I; Abou-Alfa GK
Adv Ther; 2020 Jun; 37(6):2678-2695. PubMed ID: 32424805
[TBL] [Abstract][Full Text] [Related]
5. Clinical Outcomes of 2nd- and 3rd-Line Regorafenib for Advanced Hepatocellular Carcinoma.
Naruto K; Kawaoka T; Amioka K; Ogawa Y; Chihiro K; Yoshikawa Y; Ando Y; Suehiro Y; Kosaka Y; Uchikawa S; Kodama K; Morio K; Fujino H; Murakami E; Nakahara T; Yamauchi M; Tsuge M; Hiramatsu A; Fukuhara T; Takaki S; Mori N; Tsuji K; Nonaka M; Hyogo H; Aisaka Y; Masaki K; Honda Y; Kohno H; Kohno H; Moriya T; Naeshiro N; Azakami T; Imamura M; Chayama K; Aikata H
Oncology; 2021; 99(8):491-498. PubMed ID: 34000725
[TBL] [Abstract][Full Text] [Related]
6. Multicenter retrospective analysis of the safety and efficacy of regorafenib after progression on sorafenib in Korean patients with hepatocellular carcinoma.
Yoo C; Park JW; Kim YJ; Kim DY; Yu SJ; Lim TS; Lee SJ; Ryoo BY; Lim HY
Invest New Drugs; 2019 Jun; 37(3):567-572. PubMed ID: 30523474
[TBL] [Abstract][Full Text] [Related]
7. Systemic immune-inflammation index predicts prognosis of sequential therapy with sorafenib and regorafenib in hepatocellular carcinoma.
Hong YM; Yoon KT; Cho M
BMC Cancer; 2021 May; 21(1):569. PubMed ID: 34006248
[TBL] [Abstract][Full Text] [Related]
8. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Bruix J; Qin S; Merle P; Granito A; Huang YH; Bodoky G; Pracht M; Yokosuka O; Rosmorduc O; Breder V; Gerolami R; Masi G; Ross PJ; Song T; Bronowicki JP; Ollivier-Hourmand I; Kudo M; Cheng AL; Llovet JM; Finn RS; LeBerre MA; Baumhauer A; Meinhardt G; Han G;
Lancet; 2017 Jan; 389(10064):56-66. PubMed ID: 27932229
[TBL] [Abstract][Full Text] [Related]
9. Using ALBI score at the start of sorafenib treatment to predict regorafenib treatment candidates in patients with hepatocellular carcinoma.
Yukimoto A; Hirooka M; Hiraoka A; Michitaka K; Ochi H; Joko K; Imai Y; Watanabe T; Koizumi Y; Yoshida O; Abe M; Hiasa Y
Jpn J Clin Oncol; 2019 Jan; 49(1):42-47. PubMed ID: 30380075
[TBL] [Abstract][Full Text] [Related]
10. Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study.
Bruix J; Tak WY; Gasbarrini A; Santoro A; Colombo M; Lim HY; Mazzaferro V; Wiest R; Reig M; Wagner A; Bolondi L
Eur J Cancer; 2013 Nov; 49(16):3412-9. PubMed ID: 23809766
[TBL] [Abstract][Full Text] [Related]
11. Liver function assessment according to the Albumin-Bilirubin (ALBI) grade in sorafenib-treated patients with advanced hepatocellular carcinoma.
Ogasawara S; Chiba T; Ooka Y; Suzuki E; Kanogawa N; Saito T; Motoyama T; Tawada A; Kanai F; Yokosuka O
Invest New Drugs; 2015 Dec; 33(6):1257-62. PubMed ID: 26462681
[TBL] [Abstract][Full Text] [Related]
12. Impact of albumin-bilirubin grade on survival in patients with hepatocellular carcinoma who received sorafenib: An analysis using time-dependent receiver operating characteristic.
Tada T; Kumada T; Toyoda H; Tsuji K; Hiraoka A; Michitaka K; Deguchi A; Ishikawa T; Imai M; Ochi H; Joko K; Shimada N; Tajiri K; Hirooka M; Koizumi Y; Hiasa Y; Tanaka J
J Gastroenterol Hepatol; 2019 Jun; 34(6):1066-1073. PubMed ID: 30549320
[TBL] [Abstract][Full Text] [Related]
13. Comparison between Nivolumab and Regorafenib as Second-line Systemic Therapies after Sorafenib Failure in Patients with Hepatocellular Carcinoma.
Lee HJ; Lee JS; So H; Yoon JK; Choi JY; Lee HW; Kim BK; Kim SU; Park JY; Ahn SH; Kim DY
Yonsei Med J; 2024 Jul; 65(7):371-379. PubMed ID: 38910299
[TBL] [Abstract][Full Text] [Related]
14. Sorafenib-Regorafenib Sequential Therapy in Advanced Hepatocellular Carcinoma: A Single-Institute Experience.
Ueshima K; Nishida N; Kudo M
Dig Dis; 2017; 35(6):611-617. PubMed ID: 29040994
[TBL] [Abstract][Full Text] [Related]
15. Characteristics of patients with sorafenib-treated advanced hepatocellular carcinoma eligible for second-line treatment.
Ogasawara S; Chiba T; Ooka Y; Suzuki E; Maeda T; Yokoyama M; Wakamatsu T; Inoue M; Saito T; Kobayashi K; Kiyono S; Nakamura M; Nakamoto S; Yasui S; Tawada A; Arai M; Kanda T; Maruyama H; Yokosuka O; Kato N
Invest New Drugs; 2018 Apr; 36(2):332-339. PubMed ID: 28891038
[TBL] [Abstract][Full Text] [Related]
16. Regorafenib in advanced hepatocellular carcinoma (HCC): considerations for treatment.
Kim K; Jha R; Prins PA; Wang H; Chacha M; Hartley ML; He AR
Cancer Chemother Pharmacol; 2017 Nov; 80(5):945-954. PubMed ID: 28932966
[TBL] [Abstract][Full Text] [Related]
17. Exploring the efficacy and safety of single-agent sorafenib in a cohort of Italian patients with hepatocellular carcinoma.
Santini D; Addeo R; Vincenzi B; Calvieri A; Montella L; Silletta M; Caraglia M; Vespasiani U; Picardi A; Del Prete S; Tonini G
Expert Rev Anticancer Ther; 2012 Oct; 12(10):1283-8. PubMed ID: 23094801
[TBL] [Abstract][Full Text] [Related]
18. Albumin-Bilirubin grade predicts prognosis of HCC patients with sorafenib use.
Kuo YH; Wang JH; Hung CH; Rau KM; Wu IP; Chen CH; Kee KM; Hu TH; Lu SN
J Gastroenterol Hepatol; 2017 Dec; 32(12):1975-1981. PubMed ID: 28295594
[TBL] [Abstract][Full Text] [Related]
19. Benefit-Risk Summary of Regorafenib for the Treatment of Patients with Advanced Hepatocellular Carcinoma That Has Progressed on Sorafenib.
Pelosof L; Lemery S; Casak S; Jiang X; Rodriguez L; Pierre V; Bi Y; Liu J; Zirkelbach JF; Patel A; Goldberg KB; McKee AE; Keegan P; Pazdur R
Oncologist; 2018 Apr; 23(4):496-500. PubMed ID: 29386313
[TBL] [Abstract][Full Text] [Related]
20. A multicentre comparison between Child Pugh and Albumin-Bilirubin scores in patients treated with sorafenib for Hepatocellular Carcinoma.
Edeline J; Blanc JF; Johnson P; Campillo-Gimenez B; Ross P; Ma YT; King J; Hubner RA; Sumpter K; Darby S; Evans J; Iwuji C; Swinson D; Collins P; Patel K; Muazzam I; Palmer DH; Meyer T
Liver Int; 2016 Dec; 36(12):1821-1828. PubMed ID: 27214151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
